1. Home
  2. FSCO vs LTGO Comparison

FSCO vs LTGO Comparison

Compare FSCO & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FS Credit Opportunities Corp.

FSCO

FS Credit Opportunities Corp.

SELL

Current Price

$5.05

Market Cap

1.0B

Sector

Finance

ML Signal

SELL

LTGO

Latigo Biotherapeutics Inc. Common Stock

N/A

Current Price

$14.01

Market Cap

1.2B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
FSCO
LTGO
Founded
N/A
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
2013
2026

Fundamental Metrics

Financial Performance
Metric
FSCO
LTGO
Price
$5.05
$14.01
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $52.25
AVG Volume (30 Days)
★ 1.1M
350.0K
Earning Date
05-08-2026
11-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.28
$13.50
52 Week High
$6.79
$25.93

Technical Indicators

Market Signals
Indicator
FSCO
LTGO
Relative Strength Index (RSI) 48.42 33.81
Support Level $4.90 N/A
Resistance Level $5.31 $16.56
Average True Range (ATR) 0.11 1.21
MACD -0.00 -0.16
Stochastic Oscillator 54.55 14.06

Price Performance

Historical Comparison
FSCO
LTGO

About FSCO FS Credit Opportunities Corp.

FS Credit Opportunities Corp is a closed-end management investment company. The Fund's primary investment objective is to generate an attractive total return consisting of a high level of current income and capital appreciation, with a secondary objective of capital preservation. It predominantly invests in a portfolio of secured and unsecured floating and fixed-rate loans, bonds, and other types of credit instruments. The credit instruments in which it invests are typically rated below investment grade by rating agencies or would be rated below investment grade if rated. To achieve its investment objectives, the fund focuses on strategies such as Opportunistic Credit, Special Situations, and Capital Structure Solutions.

About LTGO Latigo Biotherapeutics Inc. Common Stock

Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.

Share on Social Networks: